Literature DB >> 19604237

Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.

Tait D Shanafelt1, John C Byrd, Betsy LaPLant, Clive S Zent, Tim Call, Charla Secreto, Michael R Grever, Thomas S Lin, Neil E Kay.   

Abstract

Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti-[thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19604237      PMCID： PMC2777697          DOI： 10.1111/j.1365-2141.2009.07811.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  14 in total

1.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Authors:  Neil E Kay; Susan M Geyer; Timothy G Call; Tait D Shanafelt; Clive S Zent; Diane F Jelinek; Renee Tschumper; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Lisa Smith; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

2.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

3.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Authors:  Barbara F Eichhorst; Raymonde Busch; Georg Hopfinger; Rita Pasold; Manfred Hensel; Cordelia Steinbrecher; Siegfried Siehl; Ulrich Jäger; Manuela Bergmann; Stephan Stilgenbauer; Carmen Schweighofer; Clemens M Wendtner; Hartmut Döhner; Günter Brittinger; Bertold Emmerich; Michael Hallek
Journal:  Blood       Date:  2005-10-11       Impact factor: 22.113

Review 4.  The history of the angiogenic switch concept.

Authors:  D Ribatti; B Nico; E Crivellato; A M Roccaro; A Vacca
Journal:  Leukemia       Date:  2006-09-21       Impact factor: 11.528

5.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Authors:  Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

6.  B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.

Authors:  N E Kay; N D Bone; R C Tschumper; K H Howell; S M Geyer; G W Dewald; C A Hanson; D F Jelinek
Journal:  Leukemia       Date:  2002-05       Impact factor: 11.528

7.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

8.  Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia.

Authors:  J Gora-Tybor; J Z Blonski; T Robak
Journal:  Neoplasma       Date:  2002       Impact factor: 2.575

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Authors:  John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113
View more
  6 in total

Review 1.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

2.  Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.

Authors:  Tait Shanafelt; Clive Zent; John Byrd; Charles Erlichman; Betsy Laplant; Asish Ghosh; Timothy Call; Miguel Villalona-Calero; Diane Jelinek; Deborah Bowen; Kristina Laumann; Wenting Wu; Curtis Hanson; Neil Kay
Journal:  Leuk Lymphoma       Date:  2010-11-05

3.  Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue.

Authors:  Jennifer A Rohrs; Christopher D Sulistio; Stacey D Finley
Journal:  NPJ Syst Biol Appl       Date:  2016-10-20

4.  A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Neil E Kay; Paolo Strati; Betsy R LaPlant; Jose F Leis; Daniel Nikcevich; Timothy G Call; Adam M Pettinger; Connie E Lesnick; Curtis A Hanson; Tait D Shanafelt
Journal:  Oncotarget       Date:  2016-11-29

5.  Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.

Authors:  Carol Lozano-Santos; Jimena Martinez-Velasquez; Belen Fernandez-Cuevas; Natividad Polo; Belen Navarro; Isabel Millan; Jose Miguel Garcia; Rosa Collado; Pedro Sanchez-Godoy; Felix Carbonell; Jose Antonio Garcia-Vela; Jose Antonio Garcia-Marco; Natalia Gomez-Lozano
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

6.  Gastric carcinoma subsequent to myelodysplastic syndrome with t (1; 19) chromosome translocation: A rare case report and its potential mechanisms.

Authors:  Wenqing Yu; Gaoyang Chen; Yunpeng Sun; Sujun Gao; Wei Li; Jiuwei Cui; Jingnan Sun
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.